Heart failure is a life-threatening disease. Its prevalence is characterized by a slow, steady increase, with unacceptable high mortality. Slowing disease progression is imperative. One of the most active field is the development of novel biomarkers. Biomarkers are used in routine clinical care for diagnosis, monitoring (response to treatment), and risk stratification of patients with heart failure. In this review, we consider in 2 different sections: blood-derived and imaging biomarkers. Finally, we analyze the effect of combining these 2 categories of biomarkers available in heart failure, aiming at understanding whether their role is complementary or subtractive.
- Cardiovascular disease
- Heart failure
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine